Standardisation of von Willebrand Factor in Therapeutic Concentrates: Calibration of the 1st International Standard for von Willebrand Factor Concentrate (00/514)
- 1 January 2002
- journal article
- in focus
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 88 (09), 380-386
- https://doi.org/10.1055/s-0037-1613226
Abstract
An international study involving 26 laboratories assayed two candidate von Willebrand Factor (VWF) concentrates (B and C) for VWF:Antigen (VWF:Ag), VWF:Ristocetin Cofactor (VWF:RCo) and VWF:Collagen binding (VWF:CB) relative to the 4th International Standard Factor VIII/VWF Plasma (4th IS Plasma) (97/586). Estimates of VWF:Ag showed good agreement between different methods, for both candidates, and the overall combined means were 11.01 IU/ml with inter-laboratory variability (GCV) of 10.9% for candidate B and 14.01 IU/ml (GCV 11.8%) for candidate C. Estimates of VWF:RCo showed no significant difference between methods for both candidates and gave overall means of 9.38 IU/ml (GCV 23.7%) for candidate B and 10.19 IU/ml (GCV 24.4%) for candidate C. Prior to the calibration of the candidates for VWF:CB it was necessary to calibrate the 4th IS Plasma relative to local frozen normal plasma pools; there was good agreement between different collagen reagents and an overall mean of 0.83 IU per ampoule (GCV 11.8%) was assigned. In contrast, estimates of VWF:CB in both candidates showed large differences between collagen reagents with inter-laboratory GCV’s of 40%. Candidate B (00/514) was established as the 1st International Standard von Willebrand Factor Concentrate by the WHO Expert Committee on Biological Standardisation in November 2001 with assigned values for VWF:Ag (11.0 IU/ampoule) and VWF:RCo (9.4 IU/ampoule). Large inter-laboratory variability of estimates precluded the assignment of a value for VWF:CB.Keywords
This publication has 10 references indexed in Scilit:
- Comparison of Two von Willebrand Factor Collagen-Binding Assays with Different Binding Affinities for Low, Medium, and High Multimers of von Willebrand FactorSeminars in Thrombosis and Hemostasis, 2002
- Treatment of Von Willebrand DiseaseThrombosis and Haemostasis, 2001
- Laboratory Testing for von Willebrand’s Disease: An Assessment of Current Diagnostic Practice and Efficacy by Means of a Multi-laboratory SurveyThrombosis and Haemostasis, 1999
- Summary of a workshop on potency and dosage of von Willebrand factor concentratesHaemophilia, 1998
- New Treatments of von Willebrand Disease: Plasma Derived von Willebrand Factor ConcentratesThrombosis and Haemostasis, 1997
- Plasma Product Treatment in Various Types of von Willebrand’s DiseasePathophysiology of Haemostasis and Thrombosis, 1994
- Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand's disease type IIIAnnals of Hematology, 1992
- Comparison of the in vitro characteristics of von Willebrand factor in British and commercial factor VIII concentratesBritish Journal of Haematology, 1989
- Ristocetin-dependent reconstitution of binding of von Willebrand factor to purified human platelet membrane glycoprotein Ib-IX complexBiochemistry, 1988
- Design and analysis of accelerated degradation tests for the stability of biological standards II. A flexible computer program for data analysisJournal of Biological Standardization, 1984